



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/837,992	04/18/2001	Hui Tian	18781-006020	8880

20350 7590 01/13/2005  
TOWNSEND AND TOWNSEND AND CREW, LLP  
TWO EMBARCADERO CENTER  
EIGHTH FLOOR  
SAN FRANCISCO, CA 94111-3834

EXAMINER	
FRONDA, CHRISTIAN L	
ART UNIT	PAPER NUMBER

1652  
DATE MAILED: 01/13/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	09/837,992	TIAN ET AL.
<b>Examiner</b>	<b>Art Unit</b>	
	Christian L Fronda	1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

1)  Responsive to communication(s) filed on 26 October 2004.

2a)  This action is **FINAL**.                            2b)  This action is non-final.

3)  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## **Disposition of Claims**

4)  Claim(s) 1-7,10,11,13-15,17,18,31,32 and 76-84 is/are pending in the application.  
4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5)  Claim(s) 83 and 84 is/are allowed.

6)  Claim(s) 1,2,4-7,10,13-15,17,18,31,32 and 76-82 is/are rejected.

7)  Claim(s) 3 and 11 is/are objected to.

8)  Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

9)  The specification is objected to by the Examiner.

10)  The drawing(s) filed on 18 April 2001 is/are: a)  accepted or b)  objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)  The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

12)  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a)  All    b)  Some \* c)  None of:  
1.  Certified copies of the priority documents have been received.  
2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3.  Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

1)  Notice of References Cited (PTO-892) . . . . .  
2)  Notice of Draftsperson's Patent Drawing Review (PTO-948)  
3)  Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
    Paper No(s)/Mail Date . . . . .  
4)  Interview Summary (PTO-413)  
    Paper No(s)/Mail Date. . . . .  
5)  Notice of Informal Patent Application (PTO-152)  
6)  Other: . . . . .

Art Unit: 1652

## DETAILED ACTION

1. Claims 1-7, 10, 11, 13-15, 17, 18, 31, 32, 76-84 are pending and are under consideration in this Office Action.
2. The rejection of claims 1-7, 10, 11, 13-15, 17, 18, 31, 32, and 76 under 35 U.S.C. 112, first paragraph, as failing to meet the written description requirement has been withdrawn in view of applicants' amendment to the claims to recites that the claimed nucleic acid encodes an ATP-binding cassette (ABC) family sterol transporter.

### *Claim Rejections - 35 U.S.C. § 112, 1st Paragraph*

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:  
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
4. Claims 1, 2, 4-7, 10, 13-15, 17, 18, 31, 32, and 76-82 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an isolated polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or an isolated polynucleotide comprising SEQ ID NO: 4; does not reasonably provide enablement for any other embodiment.

Applicants' arguments filed 10/21/2004 have been fully considered but they are not persuasive. Applicants' position is that the amendments to the claims obviate the enablement rejection stated in the previous Office Action. The Examiner respectfully disagrees for reasons of record and reasons stated below.

The claims are still directed toward polynucleotides that encode polypeptides that are 75%, 80%, 90%, or 95% identical to SEQ ID NO: 3 which are not enabled by the specification. As stated in the previous Office Action, the amount of experimentation to make the claimed polynucleotides is undue and entails selecting specific nucleotides to change (deletion, insertion, substitution, or combinations thereof) in a polynucleotide to make a polynucleotide that encodes a polypeptide that comprises an amino acid sequence that is at least 75%, 80%, 90%, or 95%

Art Unit: 1652

identical to SEQ ID NO: 3 and determining by assays whether the polypeptide has ABC sterol transporter activity. Furthermore, the amount of experimentation to make the nucleic acid of claim 2 is undue and entails searching and screening for any polypeptide that binds to any polyclonal antibody generated against SEQ ID NO: 3. Teachings regarding screening and searching for the claimed invention is not guidance for making the claimed invention. Thus, claims 1, 2, 4-7, 10, 13-15, 17, 18, 31, 32, and 76-82 do not meet the enablement requirement.

### ***Conclusion***

5. Claims 83 and 84 are allowed.

6. Claims 3 and 11 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

7. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.


8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L Fronda whose telephone number is (571)272-0929. The examiner can normally be reached Monday-Friday between 9:00AM - 5:00PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura N Achutamurthy can be reached on (571)272-0928. The fax phone number for the organization where this application or proceeding is assigned is (571)273-8300.

9. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications

Art Unit: 1652

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Christian L. Fronda  
Patent Examiner  
Art Unit 1652



Manjunath Rao  
Primary Patent Examiner  
Art Unit 1652